CD80 and breast carcinoma: Finally, we evaluate differential expression with patient age among METABRIC breast cancer samples and identify a significant decrease in CD80 expression (q = 0.044) and no significant differences in the other immune-checkpoint-related genes assayed with age (Supplemental Data S2).